AQXP - Aquinox Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.66
0.00 (0.00%)
As of 1:31PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.66
Open2.68
Bid2.63 x 800
Ask2.67 x 800
Day's Range2.61 - 2.72
52 Week Range1.96 - 16.90
Volume61,645
Avg. Volume316,923
Market Cap62.609M
Beta (3Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-1.70
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Trade prices are not sourced from all markets
  • Associated Press2 months ago

    Aquinox: 2Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had net income of 12 cents. The drugmaker posted revenue of $25 million in the period. The company's shares closed at $3.07. ...

  • GlobeNewswire2 months ago

    Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results

    VANCOUVER, British Columbia, Aug. 08, 2018-- Aquinox Pharmaceuticals, Inc., a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood ...

  • ACCESSWIRE3 months ago

    These Small Biotech Companies Could Bring a 300% Return Before end of the Year

    HENDERSON NV / ACCESSWIRE / July 24, 2018 / BioRestorative Therapies, Inc. (BRTX) is a small stem cell company, that has came across our radar screen. Just a few years ago BRTX was trading as high as $10 plus per share, and a high of $3.75 this year alone. Over the last few weeks interest in BRTX has been climbing, and the company has done higher volume days recently than ever before in BRTX trading history.

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Aquinox Pharma and Three More Healthcare Stocks

    Stock Research Monitor: PRGO, RHE, and AMRX LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AQXP sign up now at www.wallstequities.com/registration . On Monday, July 23, 2018, ...

  • Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session
    Zacks3 months ago

    Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session

    Akorn (AKRX) was a big mover last session, as the company saw its shares rise more than 7% on the day, amid huge volumes.

  • Aquinox Pharmaceuticals (AQXP) Enters Oversold Territory
    Zacks3 months ago

    Aquinox Pharmaceuticals (AQXP) Enters Oversold Territory

    Aquinox Pharmaceuticals, Inc. (AQXP) has been on a bit of a cold streak lately

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Aquinox Pharmaceuticals and Summit Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Aquinox Pharmaceuticals and Summit Therapeutics both saw their shares dramatically drop on Wednesday after each company announced failed trial results. Aquinox Pharmaceuticals, Inc. shares closed down almost 85% on Wednesday and hit a new low of $2.25 on about 14.2 million shares traded. The company revealed that late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients.

  • Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today
    Motley Fool4 months ago

    Why Sonic, National Beverage, and Aquinox Pharmaceuticals Slumped Today

    One of these stocks plummeted nearly 85%.

  • Failed Trial Pushed Aquinox Down almost 83% This Morning
    Market Realist4 months ago

    Failed Trial Pushed Aquinox Down almost 83% This Morning

    Today, Aquinox (AQXP) announced that its late-stage investigational drug, the once-daily oral therapy rosiptor, failed to demonstrate a statistically significant benefit over placebo for IC (interstitial cystitis) or BPS (bladder pain syndrome) in the Phase 3 LEADERSHIP 301 clinical trial. Pursuant to this announcement, Aquinox stock crashed from $15.31 yesterday to $2.43 this morning. Aquinox may have to forego a $25 million of upfront payment, $60 million of development milestone payments, and $70 million of commercial milestone payments that it would have otherwise received based on its exclusive licensing agreement with Astellas Pharma.

  • TheStreet.com4 months ago

    Aquinox Pharma Shares Plunge 85% After Failed Test Results

    plummeted more than 80% Wednesday after late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients. "We will be halting all further development of rosiptor," David Main, CEO of Aquinox, said in a conference call Wednesday morning. The company will also stop administering rosiptor in its trial with patients afflicted with chronic prostatitis because Aquinox does not think it will benefit them in any way, Main said.

  • Reuters4 months ago

    Aquinox to stop development of lead drug; shares plunge

    Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its shares down as much as 85 percent. "We will be undertaking a thorough evaluation of our pipeline and other strategic options available to the company," Chief Executive Officer David Main said in a statement. Bladder pain syndrome, or interstitial cystitis, is a chronic condition characterized by bladder pressure, bladder pain and pelvic pain.

  • Associated Press5 months ago

    Aquinox: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 62 cents. Aquinox shares have climbed 11 percent since the beginning of the year. The stock has fallen 6.5 percent ...

  • How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?
    Simply Wall St.5 months ago

    How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?

    The most recent earnings announcement Aquinox Pharmaceuticals Inc’s (NASDAQ:AQXP) released in December 2017 suggested company earnings became less negative compared to the previous year’s level – great news for investorsRead More...

  • ACCESSWIRE7 months ago

    Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%

    Stock Monitor: Aquinox Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free earnings report on Zoetis Inc. (NYSE: ZTS ). If you want access ...

  • Associated Press7 months ago

    Aquinox reports 4Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 69 cents. For the year, the company reported that its loss widened to $50.2 million, or $2.14 per share. Aquinox ...